加拿大基于学校的HPV疫苗接种项目及政策考量
本文概述了加拿大13个省和地区基于学校的HPV疫苗接种项目实施情况与接种率,并识别了可预见的政策考量。截至2016年10月,所有13个辖区均为女孩接种,其中6个辖区将男孩纳入学校免费接种项目;11个辖区采用两剂次方案;四价疫苗为主要使用疫苗,但多数省份未来可能采用九价疫苗。
要点
- 截至2016年10月,加拿大13个辖区均在学校项目中为女孩接种HPV疫苗。
- 6个辖区的学校免费HPV接种项目纳入了男孩。
- 11个辖区采用两剂次接种方案,四价疫苗为加拿大主要使用疫苗。
核心结论
- 未来研究和创新将有益于加拿大各辖区在考虑是否接种九价疫苗、实施两剂还是一剂接种方案以及如何提高接种率和完成率时提供信息。
- 确定HPV疫苗接种覆盖率收集和报告方法标准化以及实施国家登记系统的有用性为重要优先事项。
研究设计与样本
- 研究检索了学术和灰色文献,并联系省和地区疫苗接种项目管理者,以汇编加拿大13个省和地区辖区的HPV疫苗项目管理和接种率信息。
主要发现
- 截至2016年10月,所有13个加拿大辖区为女孩接种疫苗,6个辖区将男孩纳入学校免费HPV疫苗接种项目。
- 11个辖区采用两剂次方案接种HPV疫苗。
- 四价疫苗(HPV4)一直是加拿大主要使用的疫苗,但大多数省份未来可能采用九价疫苗。
- 根据现有数据,女性接种率范围在46.7%至93.9%之间,男性接种率(在有可用数据的项目中)范围在75.0%至87.4%之间。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The National Advisory Committee on Immunization in Canada recommends human papillomavirus (HPV) vaccination for females and males (ages 9-26). In Canada, the HPV vaccine is predominantly administered through publicly funded school-based programs in provinces and territories. This research provides an overview of Canadian provincial and territorial school-based HPV vaccination program administration and vaccination rates, and identifies foreseeable policy considerations. METHODS: We searched the academic and grey literature and contacted administrators of provincial and territorial vaccination programs to compile information regarding HPV vaccine program administration and vaccination rates in Canada's 13 provincial and territorial jurisdictions. RESULTS: As of October 2016, all 13 Canadian jurisdictions vaccinate girls, and six jurisdictions include boys in school-based publicly funded HPV vaccination programs. Eleven jurisdictions administer the HPV vaccine in a two-dose schedule. The quadrivalent vaccine (HPV4) has been the vaccine predominantly used in Canada; however, the majority of provinces will likely adopt the nonavalent vaccine in the future. According to available data, vaccination uptake among females ranged between 46.7% and 93.9%, while vaccination uptake among males (in programs with available data to date) ranged between 75.0% and 87.4%. CONCLUSIONS: Future research and innovation will beneficially inform Canadian jurisdictions when considering whether to administer the nonavalent vaccine, whether to implement a two or one-dose vaccination schedule, and how to improve uptake and rates of completion. The usefulness of standardizing methodologies for collecting and reporting HPV vaccination coverage and implementing a national registry were identified as important priorities.
引用
- Shapiro GK, Guichon J, Kelaher M, et al. Canadian school-based HPV vaccine programs and policy considerations. Vaccine. 2017. PMID: 28893472. doi:10.1016/j.vaccine.2017.07.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。